De Wit R, et al. CARD: randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer. ESMO Congress 2019, abstract LBA13_PR. ,De Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. NEJM 2019, online 30 september, DOI: 10.1056/NEJMoa1911206.
ECCO 2017: Grote verschillen in Nederland bij opvolgen behandelrichtlijnen kanker
jan 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie, Uro-oncologie